| Literature DB >> 35821838 |
Francisco José Naranjo-Galindo1,2, Ruixue Ai1, Evandro Fei Fang1, Hilde Loge Nilsen1,2,3, Tanima SenGupta1,2.
Abstract
Since its introduction as a genetic model organism, Caenorhabditis elegans has yielded insights into the causes of aging. In addition, it has provided a molecular understanding of mechanisms of neurodegeneration, one of the devastating effects of aging. However, C. elegans has been less popular as an animal model to investigate DNA repair and genomic instability, which is a major hallmark of aging and also a cause of many rare neurological disorders. This article provides an overview of DNA repair pathways in C. elegans and the impact of DNA repair on aging hallmarks, such as mitochondrial dysfunction, telomere maintenance, and autophagy. In addition, we discuss how the combination of biological characteristics, new technical tools, and the potential of following precise phenotypic assays through a natural life-course make C. elegans an ideal model organism to study how DNA repair impact neurodegeneration in models of common age-related neurodegenerative diseases.Entities:
Keywords: Alzheimer’s disease; Caenorhabditis elegans; DNA repair; Parkinson’s disease; aging; neurodegenerative diseases
Year: 2022 PMID: 35821838 PMCID: PMC9261396 DOI: 10.3389/fragi.2022.916118
Source DB: PubMed Journal: Front Aging ISSN: 2673-6217
FIGURE 1Hallmarks of aging and neurodegeneration in C. elegans. The hallmarks of aging and neurodegeneration in C. elegans include genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, and altered cell communication. The figure has been generated using Biorender.com by the author.
FIGURE 2C. elegans as model organism to study mitochondrial homeostasis and function. The C. elegans provide a way to monitor mitophagy; 1: Mitochondria-target Rosella (mtRosella), using the Rosella biosensor combining a pH-insensitive DsRed and pH-insensitive GFP. 2: Co-localization between DCT-1 (outer mitochondrial membrane protein) and LGG-1 (autophagosomal membrane protein, homolog of the mammalian LC3). 3: Luciferase-based methods to evaluate how different conditions affects the production of ATP in C. elegans; The Roche ATP bioluminescent assay kit HSII is another way to determine ATP content. 4: TMRM: the TMRM staining-tetramethylrhodamine, ethyl ester, perchlorate, a dye that accumulates in intact, respiring mitochondria. 5: Oxygen consumption rate (OCR) is another parameter to reflect mitochondria function. 6: Mito Tracker Green FM is a green-fluorescent dye that stains mitochondria in live cells and its accumulation is dependent on membrane potential. 7: mitochondrial ROS and cellular ROS can be quantification via mtROS (MitoTracker Red CM-H2X ROS); DHE (dihydroethidium), respectively. 8: Stress resistance-survival can also be detected via a heat stress assay, CCCP stress assay, ultraviolet light stress assay, paraquat-induced oxidative stress assay and starvation assays. The figure has been generated using power point image building tool by the author.
FIGURE 3C. elegans DNA repair pathways. The excision repair pathways BER, NER, DSB and MMR are operative in C. elegans. Using C. elegans various neurodegenerative diseases like AD, PD, XP, CS and AT associated to DNA repair defects has been modeled. The figure has been generated using Biorender.com by the author.
FIGURE 4C. elegans to study NDs. The nematode allows for different perspectives in the study and understanding of NDs. Left. Protein misfolding and aggregation is one of the common features of different NDs. The transparency of C. elegans in combination with the use of fluorescent tags allows for the in vivo visualization of the protein aggregation process in the NDs of interest. Center. A consequence of the progression of NDs is the degeneration of the affected neurons. Strains can be engineered to express the aggregating proteins in the neuronal circuit of interest in the nematode, allowing to study the neurodegeneration process. Right. The morphological changes, featured in the different ND models like aggregation or neurodegeneration, also translate into functional challenges. The performance in the different available assays corresponds to the health status of the neuron/s of interest. Bottom. The above-mentioned assessments of an ND using C. elegans can be combined with available mutant strains for the gene/s of interest, or with screenings, either with the available existing RNAi libraries, to find genetic modulators; or compound screenings where chemical regulators of the ND progression can be discovered. The figure has been generated using Biorender.com by the author.
C. elegans strains used to model neurodegenerative disease.
| NDD | Strain | Genotype | Tissue | Use | Reference |
|---|---|---|---|---|---|
| PD | BY273 |
| DA neurons | Expression of α-synuclein in DA neurons to assess neurodegeneration and its functional effect |
|
| Panneuronal-WTα-syn |
| Pan-neuronal | Panneuronal expression of WT α-syn to assess neurodegeneration and its functional effect |
| |
| Dopaminergic-A53Tα-syn |
| DA neurons | Dopaminergic expression of mutant α-syn (A53T) to assess neurodegeneration and its functional effect |
| |
| Panneuronal-A53Tα-syn |
| Pan-nenuronal | Panneuronal expression of α-syn (A53T) to assess neurodegeneration and its functional effect |
| |
| UA44 |
| DA neurons | Expression of α-synuclein in DA neurons to assess neurodegeneration and its functional effect |
| |
| UA49 |
| Muscle | Expression of α-synuclein in muscle to assess the aggregation process |
| |
| UA50 |
| Muscle | Expression of α-synuclein in muscle to assess the aggregation process but at a reduced rate due to the expresion of TOR2 |
| |
| NL5901 |
| Muscle | Expression of α-synuclein in muscle to assess the aggregation process |
| |
| JVR406 |
| Serotonergic neurons (tph-1p) and head, tail, ventral and dorsal nerve cords (ddr-2p) | Expression of α-synuclein in two different neural circuits expressing BiFC when there is a transfer of α-synuclein between the two neuronal populations | Tyson et al. (2017) Sci Rep. 2017 August 8; 7 (1):7506 | |
| AD | CL2355 |
| Pan-neuronal | Pan-neuronal expression of hAβ3-42 | Wu et al. J Neurosci. 2006 December 13; 26 (50):13102–13 |
| JKM2 |
| Pan-neuronal | Pan-neuronal expression of hAβ1-42 | Gallrein et al. Progress in Neurobiology 198 (2021): 101907 | |
| UA198 |
| Glutamatergic neuron | Glutamatergic neuronal expression of the hAβ1-42 |
| |
| BR5270 |
| Pan-neuronal | Pan-neuronal expression of the human tau mutant hTau [F3Δ280] | Fatuouros et al. Hum Mol Genet. 2012 August 15; 21 (16):3587–603 | |
| CK12 |
| Pan-neuronal | Pan-neuronal expression of the human tau mutant hTau [P301L] | Kraemer et al. Proc Natl Acad Sci USA 100.17 (2003): 9980–9985 | |
| FX11962 |
| Pan-neuronal | Pan-neuronal expression of the human WT tau0N4R at low level (no memory impairment) | Miyasaka et al. Front Neurosci 12 (2018): 415 | |
| FX11974 |
| Pan-neuronal | Pan-neuronal expression of the human WT tau0N4R at high level with memory impairment | Miyasaka et al. Front Neurosci 12 (2018): 415 | |
| UM0001 |
| Pan-neuronal | Pan-neuronal expression of hAβ1-42; hTau [F3Δ280] | Yang et al. Aging (Albany NY) 12.17 (2020): 16852 | |
| HD | ID1 |
| Mechanosensory neurons | Expression of polyQ repeats (128Q) in touch receptor neurons, resulting in extended aggregation in the mechanosensory neuronal circuit and mec phenotype |
|
| ID245 |
| Mechanosensory neurons | Expression of polyQ repeats (19Q) in touch receptor neurons resulting in very low/rare aggregation in the mechanosensory neuronal circuit |
| |
| AM140 |
| Muscle | Expression of polyQ repeats (35Q) in muscle. Soluble in early stages transitioning to aggregation in adult stage |
| |
| AM141 |
| Muscle | Expression of polyQ repeats (40Q) in muscle. Rapid aggregation since early stages showing a full aggregation phenotype in adulthood |
| |
| AM101 |
| Pan-neuronal | Pan-neuronal expression of polyQ repeats (40Q) resulting in neuronal dysfunction |
| |
| Prion-like Q25 |
| Pharyngeal muscle (myo-2p) and pharyngeal neurons (flp-21p) | Expression of 25Q in two different tissues expressing BiFC when there is a transfer of polyQ between the different tissues |
| |
| Prion-like Q97 |
| Pharyngeal muscle (myo-2p) and pharyngeal neurons (flp-21p) | Expression of 97Q in two different tissues expressing BiFC when there is a transfer of polyQ between the different tissues |
| |
| ALS | Panneuronal-Human WT SOD1 |
| Pan-neuronal | Expression of panneuronal WT human SOD1 |
|
| Panneuronal-Human-G85R-SOD1 |
| Pan-neuronal | Expression of panneuronal mutant G85R human SOD1 resulting in locomotor defects and aggregation |
| |
| Panneuronal-Human WT SOD1 |
| Pan-neuronal | Expression of panneuronal WT human SOD1 tagged with YFP |
| |
| Panneuronal-Human-G85R-SOD1 |
| Pan-neuronal | Expression of panneuronal mutant G85R human SOD1 resulting in locomotor defects and aggregation |
| |
| CL6049 |
| Pan-neuronal | Expression of pan-neuronal WT human TDP43 |
| |
| alfa-1 mutant (5x outcrossed) + GABA tag |
| GABAergic neurons | Deletion mutant of alfa-1 (orthologue of human C9ORF72) with GABAergic neurons tagged. Observable degeneration of that neuronal circuit, locomotion defects and sensitive to osmotic stress |
| |
| GABAergic-DPR (GR)50 |
| GABAergic neurons | Expression of GABAergic DPR (GR)50 resulting in locomotion defects and blebbing in the GABAergic circuit |
| |
| GABAergic-DPR (PR)50 |
| GABAergic neurons | Expression of GABAergic DPR (PR)50 resulting in locomotion defects and blebbing in the GABAergic circuit |
| |
| Muscle-DPR (GR)50 |
| Muscle | Expression of muscle DPR (GR)50 resulting in locomotion defects and brood size decrease |
| |
| Muscle-DPR (PR)50 |
| Muscle | Expression of muscle DPR (PR)50 resulting in locomotion defects and brood size decrease |
|
FIGURE 5Innovative workflows using C. elegans to study NDs. The development of new workflows and or techniques in the nematode allows for news scopes in the study of NDs, allowing to switch between whole-organism to single cell perspectives, at one’s convenience. (Top). A strain can be generated by CRISPR in order to tag with a fluorescence marker (pink) the tissue of interest. Posteriorly, large synchronized populations of the strain can be raised and chemically digested, in order to obtain a cell suspension that be FACS sorted based on the fluorescence tag. The resulting sorted population can be used in different analyses and techniques, where small variations could be masked if analysing whole worms. (Bottom). A strain can be generated by CRISPR in order to tag biochemically (green) the transcripts produced in the tissue of interest. Posteriorly, large synchronized populations of the strain can be raised and whole organism extraction is performed, but the creation of the transcript library will be biased by the presence of the biochemical tag. Following transcriptional analysis will inform specifically about changes in the tissue of interest. The figure has been generated using Biorender.com by the author.